Iprasol Inhaler (100 mcg + 20 mcg)/puff is a fixed-dose combination bronchodilator inhaler containing Salbutamol and Ipratropium Bromide. It is designed to provide effective relief from bronchospasm by combining two complementary mechanisms of action. This inhaler is widely used in the management of chronic obstructive pulmonary disease (COPD) and as adjunctive therapy in bronchial asthma, particularly in patients who do not achieve adequate symptom control with single-agent bronchodilators. The metered-dose inhaler ensures targeted delivery to the lungs, resulting in rapid onset of action and minimal systemic effects.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Combined Bronchodilators
Beta₂-Agonist and Anticholinergic Agents

Composition

Each metered puff delivers:

• Salbutamol 100 mcg

• Ipratropium Bromide 20 mcg

Indications

Iprasol Inhaler (100 mcg + 20 mcg)/puff is indicated for:

• Management of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema

• Adjunctive treatment of bronchial asthma

• Relief of reversible airway obstruction in patients requiring combination bronchodilator therapy

It is particularly useful for patients who experience persistent symptoms despite treatment with a single bronchodilator.

Pharmacology

Salbutamol is a short-acting, selective beta₂-adrenergic agonist that relaxes bronchial smooth muscle by stimulating beta₂ receptors, leading to rapid bronchodilation and improved airflow. Ipratropium Bromide is an anticholinergic agent that blocks muscarinic receptors in the airways, inhibiting acetylcholine-induced bronchoconstriction. The combined action of these two agents results in enhanced bronchodilation, improved lung function, and prolonged symptom relief. Both drugs act mainly within the respiratory tract, which helps limit systemic absorption and reduces the risk of systemic adverse effects.

Dosage and Administration

The dosage of Iprasol Inhaler should be individualized according to the patient’s clinical condition and response to therapy.

• Commonly administered as one or two puffs at regular intervals as prescribed by a physician

• Patients should be instructed on proper inhalation technique to ensure effective delivery of the medication

The inhaler should be used regularly as advised and should not be exceeded beyond the recommended dose.

Contraindications

Iprasol Inhaler is contraindicated in patients with:

• Known hypersensitivity to salbutamol, ipratropium bromide, atropine, or any component of the formulation

• History of allergic reactions to similar bronchodilator agents

Precautions and Warnings

• Use with caution in patients with cardiovascular disorders, hypertension, diabetes mellitus, or hyperthyroidism

• Caution is advised in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction

• Avoid spraying the inhaler into the eyes

• Not intended as the sole therapy for severe acute asthma attacks unless specifically directed by a healthcare professional

Adverse Effects

Iprasol Inhaler is generally well tolerated. Possible adverse effects include:

• Tremor

• Dry mouth

• Headache

• Palpitations

• Throat irritation or cough

These effects are usually mild and transient.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

Caution is advised when used with:

• Other beta-agonists or anticholinergic medicines

• Beta-blockers

• Diuretics or corticosteroids, which may increase the risk of hypokalemia

Storage

Store in a cool and dry place, away from direct heat and sunlight. Do not puncture or expose the canister to high temperatures. Keep out of reach of children.

Conclusion

Iprasol Inhaler (100 mcg + 20 mcg)/puff offers effective dual bronchodilation through the combined action of salbutamol and ipratropium bromide. Its rapid onset, enhanced bronchodilatory effect, and convenient inhaler form make it a valuable option for the management of COPD and asthma-related bronchospasm.